Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.72 |
| ▸ | PPARG | P37231 | 11/20 | 0.60 |
| ▸ | PPARA | Q07869 | 11/20 | 0.60 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6475650 | 0.88 | PPARD (0.71) | PPARDPPARGPPARAMAOB | |
| SCHEMBL6474159 | 0.87 | PPARD (0.74) | PPARDPPARGPPARACYP4F2CYP4A11 | |
| SCHEMBL6475165 | 0.84 | PPARD (0.69) | PPARDPPARGPPARA | |
| SCHEMBL6475169 | 0.84 | PPARD (0.69) | PPARDPPARGPPARA | |
| SCHEMBL6475171 | 0.84 | PPARD (0.69) | PPARDPPARGPPARA | |
| SCHEMBL6480506 | 0.84 | PPARD (1.00) | PPARDPPARGPPARAFFAR1FFAR4 | |
| SCHEMBL2293786 | 0.81 | CYP4F2 (0.72) | CYP4F2CYP4A11FFAR1FFAR4 | |
| SCHEMBL6419214 | 0.79 | PPARD (0.82) | PPARDPPARGPPARA | |
| SCHEMBL6419154 | 0.79 | PPARD (0.82) | PPARDPPARGPPARA | |
| SCHEMBL6480760 | 0.78 | PPARD (0.74) | PPARDPPARGPPARAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| EP-1414778-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | EP | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
| WO-2003011807-A1 | NOVEL VINYL CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS ETC. | NOVO NORDISK A/S (DK) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.